Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Relay Therapeutics, Inc. on June 3, 2024. The filing details the voting outcomes for three specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors
- Sanjiv K. Patel, M.D.: Elected with 109,894,794 votes for, 1,587,504 votes withheld, and 8,190,121 broker non-votes.
- Linda A. Hill, Ph.D.: Elected with 91,335,004 votes for, 20,111,439 votes withheld, and 8,225,976 broker non-votes.
- Proposal 2: Non-binding Advisory Vote on Executive Compensation
- Approved by shareholders with 66,749,846 votes for, 44,678,968 votes against, and 53,582 abstentions.
- Proposal 3: Ratification of Independent Registered Public Accounting Firm
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2024, with 119,407,293 votes for, 19,856 votes against, and 245,270 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director Linda A. Hill, Ph.D. (20,111,439) compared to Sanjiv K. Patel, M.D. (1,587,504).
- Note the substantial opposition to the executive compensation proposal, with 44,678,968 votes cast against the measure.
- Confirm the ratification of Ernst & Young LLP as the independent auditor for the 2024 fiscal year.